SUZHOU, China and MÖLNDAL, Sweden, Nov. 9, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for SR122, a dual GalNAc...
Hence then, the article about ribo submits european clinical trial application for a novel dual targeting sirna sr122 for mixed and severe dyslipidemia further strengthening its footprint in the area of lipid disorder was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ribo Submits European Clinical Trial Application for a Novel Dual Targeting siRNA SR122 for Mixed and Severe Dyslipidemia, Further Strengthening Its Footprint in the Area of Lipid Disorder )
Also on site :
- Chipotle Is Bringing Back Its Record-Breaking BOGO Deal on Friday the 13th—With a Limited-Edition Wiz Khalifa Bag—And You Don’t Even Need a Real Tattoo
- ‘American Idol’ Star Reveals Dark Spiral After Hollywood Dreams Crumbled: ‘I Became Less and Less Like Myself’
- Billboard to Update Chart Methodology in 2027 Following Annual Industry Revenue Review